- Home
- SGN vs APRE Comparison
SGN vs APRE Comparison
Compare SGN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- APRE
- Stock Information
- Founded
- SGN 2019
- APRE 2006
- Country
- SGN United States
- APRE United States
- Employees
- SGN N/A
- APRE N/A
- Industry
- SGN
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGN
- APRE Health Care
- Exchange
- SGN Nasdaq
- APRE Nasdaq
- Market Cap
- SGN 7.8M
- APRE 8.3M
- IPO Year
- SGN 2023
- APRE 2019
- Fundamental
- Price
- SGN $1.48
- APRE $1.40
- Analyst Decision
- SGN
- APRE Strong Buy
- Analyst Count
- SGN 0
- APRE 1
- Target Price
- SGN N/A
- APRE $20.00
- AVG Volume (30 Days)
- SGN 220.9K
- APRE 142.4K
- Earning Date
- SGN 11-12-2025
- APRE 11-07-2025
- Dividend Yield
- SGN N/A
- APRE N/A
- EPS Growth
- SGN N/A
- APRE N/A
- EPS
- SGN N/A
- APRE N/A
- Revenue
- SGN $391,126.00
- APRE $841,012.00
- Revenue This Year
- SGN N/A
- APRE N/A
- Revenue Next Year
- SGN N/A
- APRE N/A
- P/E Ratio
- SGN N/A
- APRE N/A
- Revenue Growth
- SGN N/A
- APRE N/A
- 52 Week Low
- SGN $0.44
- APRE $1.31
- 52 Week High
- SGN $13.72
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- SGN 41.28
- APRE 42.88
- Support Level
- SGN $1.38
- APRE $1.31
- Resistance Level
- SGN $1.66
- APRE $1.49
- Average True Range (ATR)
- SGN 0.12
- APRE 0.09
- MACD
- SGN -0.02
- APRE -0.01
- Stochastic Oscillator
- SGN 20.08
- APRE 23.68
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.